End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age

British Journal of Cancer

Volumn 105, Issue 1, 2011, Pages 28-37

  Castellsague X ^a   Muoz N ^b   Pitisuttithum, P ^c   Ferris, D ^d   Monsonego, J ^e   Ault, K ^f   Luna, J ^b   Myers, E ^g   Mallary, S ^h   Bautista, O M ^h   Bryan, J ^h   Vuocolo, S ^h   Haupt, R M ^h   Saah, A ^h  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b Instituto Nacional de Cancerología   (Colombia)

^c MAHIDOL UNIVERSITY   (Thailand)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e Fédération Mutualiste Parisienne ^*  (France)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

adult; cervical; HPV; vaccine

Indexed keywords

DNA; PLACEBO; RECOMBINANT VACCINE; WART VIRUS VACCINE;

ADULT; ARTICLE; BREAST CANCER; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FACE EDEMA; FATIGUE; FEMALE; FOLLOW UP; GENITAL SYSTEM DISEASE; HEART ARREST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INJECTION SITE SWELLING; LIVER DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METASTASIS; MOUTH ULCER; NONHUMAN; PAPANICOLAOU TEST; PERICARDITIS; PRIORITY JOURNAL; TUBERCULOSIS; URTICARIA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; OVARIAN NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VACCINATION; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 79959765563     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.185     Document Type: Article

References (21)

1. Castellsague X, Schneider A, Kaufmann AM, Bosch FX (2009) HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 115(Suppl 3): S15-S23
2. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366(9490): 991-998 (Pubitemid 41323035)
3. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7(7): 453-459 (Pubitemid 46962343)
4. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE (2007) Prevalence of HPV infection among females in the United States. JAMA 297: 813-819 (Pubitemid 46333946)
5. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan JT, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19): 1928-1943 (Pubitemid 46740303)
6. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E (2007) Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer 2: 15
7. International Agency for Research on Cancer Working Group. Human Papillomaviruses. [90]. (2007). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC: Lyon, France, IARC.
8. Jacobs MV, Walboomers JMM, Snijders PJF, Voorhorst FJ, Verheijen RHM, Fransen-Daalmeijer N, Meijer CJLM (2000) Distribution of 37 mucoso-tropic HPV types in women with cytologically normal cervial smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 87: 221-227 (Pubitemid 30434349)
9. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch X, Dillner J, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Lu S, Vuocolo S, Hesley TM, Haupt RM, Barr E (2008) HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26(52): 6844-6851
10. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsaguë X, Shah KV, Snijders PJF, Meijer CJLM, for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6): 518-527 (Pubitemid 36159887)
11. Muñoz N, Castellsague X, de Gonzalez AB, Gissmann L (2006) HPV in the etiology of human cancer. Vaccine 24(Suppl 3): S1-S10
12. Munoz N, Manalastas R, Pitisuttihum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo F, Esser M, Vuocolo S, Haupt R, Barr E, Saah A (2009) Safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age: a randomized, double-blind trial. Lancet 373: 1921-1922
13. Munoz N, Mendez F, Posso H, Molano M, van den Brule AJ, Ronderos M, Meijer C, Munoz A, Instituto Nacional de Cancerologia HPV study group (2004) Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 15(190): 2077-2087 (Pubitemid 39636354)
14. Olsson S-E, Villa LL, Costa R, Petta C, Andrade R, Malm C, Iversen O-E, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms G, Giacoletti K, Lupinacci L, Esser M, Vuocolo S, Saah AJ, Barr E (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 viruslike-particle vaccine. Vaccine 25: 4931-4939 (Pubitemid 46843434)
15. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT (2003) Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10(1): 108-115 (Pubitemid 36133838)
16. Rodriguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, Solomon D, Guillen D, Alfaro M, Morales J, Hutchinson M, Katki H, Cheung L, Wacholder S, Burk RD (2010) Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/ 3: critical role of duration of infection. J Natl Cancer Inst 102(5): 315-324
17. Schiffman M, Kjaer SK (2003) Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31: 14-19
18. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright Jr T, Young N (2002) The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287(16): 2114-2119 (Pubitemid 34437346)
19. The FUTURE II Study Group (2007a) Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virologic evidence of HPV infection. J Infect Dis 196(10): 1438-1446
20. The FUTURE II Study Group (2007b) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19): 1915-1927
21. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer A, Shah KV, Snijders PJF (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1): 12-19 (Pubitemid 29406813)